SGLT2 inhibition potentiates the cardiovascular, renal, and metabolic effects of sGC stimulation in hypertensive rats with prolonged exposure to high-fat diet

• Published in: American journal of physiology. Heart and circulatory physiology Vol. 322; no. 4; p. H523
• Main Authors: Reverte, Virginia, Rodriguez, Francisca, Oltra, Lidia, Moreno, Juan M, Llinás, María T, Shea, Courtney M, Schwartzkopf, Chad D, Buys, Emmanuel S, Masferrer, Jaime L, Salazar, F Javier
• Format: Journal Article
• Language: English
• Published: United States 01-04-2022
• Subjects: Animals; Benzhydryl Compounds - pharmacology; Creatinine; Diet, High-Fat - adverse effects; Glucose; Hypertension; Insulin Resistance; Leptin; Rats; Sodium-Glucose Transporter 2; Soluble Guanylyl Cyclase; Triglycerides; sGC stimulation; hypertension; insulin resistance; SGLT2 inhibition; high-fat diet
• ISSN: 1522-1539
• DOI: 10.1152/ajpheart.00386.2021

Prolonged high-fat diet (HFD) accelerates the cardiovascular, renal, and metabolic dysfunction in hypertensive rats with altered renal development (ARDev). Soluble guanylate cyclase (sGC) stimulation or sodium-glucose cotransporter 2 (SGLT2) inhibition may improve cardiovascular, renal, and metabolic function in settings of hypertension and obesity. This study examined whether 6 wk treatment with an SGLT2 inhibitor (empagliflozin, 7 mg/kg/day) enhances the cardiovascular, renal, and metabolic effects of a sGC stimulator (praliciguat, 10 mg/kg/day) in hypertensive rats with ARDev and prolonged exposure to HFD. Arterial pressure (AP), renal vascular resistance (RVR), fat abdominal volume (FAV), insulin resistance, leptin and triglycerides levels, and intrarenal infiltration of inflammatory cells were higher, but cardiac output and creatinine clearance were lower in hypertensive rats (
= 15) than in normotensive rats (
= 7). Praliciguat administration (
= 10) to hypertensive rats reduced (
< 0.05) AP, FAV, plasma concentrations of leptin and triglycerides, and increased (
< 0.05) cardiac output and creatinine clearance. Empagliflozin administration (
= 8) only increased (
< 0.05) glucosuria and creatinine clearance and decreased (
< 0.05) plasma leptin and triglycerides concentrations in hypertensive rats. Simultaneous administration of praliciguat and empagliflozin (
= 10) accelerated the decrease in AP, improved glucose tolerance, reduced (
< 0.05) incremental body weight gain, and decreased (
< 0.05) insulin resistance index, RVR, and the infiltration of T-CD3 lymphocytes in renal cortex and renal medulla. In summary, the combined administration of praliciguat and empagliflozin leads to a greater improvement of the cardiovascular, renal, and metabolic dysfunction secondary to prolonged exposure to HFD in hypertensive rats with ARDev than the treatment with either praliciguat or empagliflozin alone.
This is the first study, to our knowledge, showing that SGLT2 inhibition potentiates the beneficial cardiovascular, renal, and metabolic effects elicited by sGC stimulation in hypertensive rats with prolonged high-fat diet. The effects of the simultaneous administration of praliciguat and empagliflozin are greater than those elicited by either one alone. The effects of the simultaneous treatment may be related to a greater reduction in the inflammatory status.